PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On April 21, 2017, the NYSE MKT LLC (the “NYSE MKT”) filed a Form 25 with the Securities and Exchange Commission (the “SEC”), notifying the SEC of the NYSE MKT’s intention to remove the shares of common stock (“Common Stock”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and the Company’s class of warrants with an exercise price of $0.85 per share expiring June 19, 2020 (the “Listed Warrants”) from listing and registration on the NYSE MKT effective May 1, 2017, to the provisions of Rule 12d2-2(b) of the Securities Exchange Act of 1934, as amended. The NYSE MKT’s filing of the Form 25 followed the NYSE MKT Committee for Review’s determination on April 5, 2017 to affirm the January 31, 2017 decision of the NYSE MKT Listing Qualifications Panel to initiate delisting proceedings due to (i) the “abnormally low” trading price of the shares of the Common Stock and (ii) the Company’s noncompliance with Section 1003(a)(iii) of the NYSE MKT Company Guide (requiring stockholders’ equity of $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years).

The Common Stock and Listed Warrants will continue to trade on the OTCQB following the delisting from the NYSE MKT under the trading symbols “PVCT” and “PVCTWS,” respectively. The Company can provide no assurance that the Common Stock and Listed Warrants will continue to trade on the OTCQB in the future.

Story continues below


About PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT)

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Recent Trading Information

PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) closed its last trading session down -0.0039 at 0.0531 with 6,437,130 shares trading hands.

An ad to help with our costs